Eli Lilly's Foundayo Weight-Loss Pill Launches on LillyDirect; Morgan Stanley Raises PT
LLY sits 51% above its 52-week low of $623.78.
Summary
Eli Lilly has officially launched Foundayo (orforglipron), its new once-daily weight-loss pill, on its direct-to-consumer platform, LillyDirect, as of April 10, 2026. This commercial availability follows the drug's significant FDA approval on April 1st, which was previously reported. The launch is a critical step in bringing this highly anticipated product to market, with initial pricing at $149/month. This move is expected to be a key driver for future revenue growth in the competitive weight-loss sector. Separately, Morgan Stanley increased its price target for Eli Lilly to $1,327 from $1,313, reflecting positive analyst sentiment following the drug's market entry.
At the time of this announcement, LLY was trading at $939.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $887.6B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.